Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial

Lavigne-Lissalde, G; Aya, A G; Mercier, F J; Roger-Christoph, S; Chauleur, C; Morau, E; Ducloy-Bouthors, A S; Mignon, A; Raucoules, M; Bongain, A; Boehlen, Françoise; De Moerloose, Philippe; Bouvet, S; Fabbro-Peray, P; Gris, J-C

doi:10.1111/jth.12844

Scientific article

English

Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial

ContributorsLavigne-Lissalde, G; Aya, A G; Mercier, F J; Roger-Christoph, S; Chauleur, C; Morau, E; Ducloy-Bouthors, A S; Mignon, A; Raucoules, M; Bongain, A; Boehlen, Françoise; De Moerloose, Philippe; Bouvet, S; Fabbro-Peray, P; Gris, J-C

Published inJournal of thrombosis and haemostasis, vol. 13, no. 4, p. 520-529

Publication date2015

Abstract

Case reports on recombinant human factor VIIa (rhuFVIIa) use in women with severe postpartum hemorrhage (PPH) showed encouraging results, but no randomized controlled trial (RCT) is available.

Keywords

Adult
Coagulants/administration & dosage/adverse effects/therapeutic use
Compassionate Use Trials
Dinoprostone/analogs & derivatives/therapeutic use
Drug Administration Schedule
Factor VIII/administration & dosage/adverse effects/therapeutic use
Female
France
Hemostatic Techniques/adverse effects
Humans
Hysterectomy
Infusions, Intravenous
Postpartum Hemorrhage/diagnosis/drug therapy/mortality
Pregnancy
Risk Factors
Severity of Illness Index
Switzerland
Time Factors
Treatment Failure
Venous Thrombosis/chemically induced

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Geneva Platelet Group (13)

Citation (ISO format)

LAVIGNE-LISSALDE, G et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. In: Journal of thrombosis and haemostasis, 2015, vol. 13, n° 4, p. 520–529. doi: 10.1111/jth.12844

Article (Published version)

Identifiers

PID : unige:89774
DOI : 10.1111/jth.12844
PMID : 25594352

Journal ISSN1538-7836

416views

0downloads

Creation10/31/2016 2:24:00 PM

First validation10/31/2016 2:24:00 PM

Update time03/15/2023 2:04:00 AM

Status update03/15/2023 2:03:59 AM

Last indexation10/31/2024 6:21:58 AM

Archive ouverte UNIGE

Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial

Case reports on recombinant human factor VIIa (rhuFVIIa) use in women with severe postpartum hemorrhage (PPH) showed encouraging results, but no randomized controlled trial (RCT) is available.

Technical informations